[Federal Register Volume 69, Number 105 (Tuesday, June 1, 2004)]
[Notices]
[Pages 30946-30947]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-12238]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Center for Substance Abuse Prevention; Notice of Meeting

    Pursuant to Pub. L. 92-463, notice is hereby given of the meeting 
of the Substance Abuse and Mental Health Services Administration 
(SAMHSA) Drug Testing Advisory Board to be held in June 2004.

[[Page 30947]]

    On June 8, the Board will meet in open session from 8:30 a.m. to 
11:30 a.m. The open session will include a Department of Health and 
Human Services drug testing program update, a presentation on the 
revisions to the ``Mandatory Guidelines for Federal Workplace Drug 
Testing'' published in the Federal Register on April 13, 2004 (69 FR 
19644-19673), and a Department of Transportation drug testing program 
update. If anyone needs special accommodations for persons with 
disabilities, please notify the Contact listed below.
    The Board will meet in closed session on June 8, from 11:30 a.m. to 
4:30 p.m. to review and evaluate proprietary testing processes and 
procedures of drug testing laboratories certified to perform drug 
testing in accordance with the ``Mandatory Guidelines for Federal 
Workplace Drug Testing Programs'' (Mandatory Guidelines) published in 
the Federal Register (59 FR 29908-29931 on June 9, 1994, 63 FR 51118-
51119 on September 30, 1997, and 63 FR 63483 on November 13, 1998). 
Public disclosure of information concerning proprietary laboratory 
testing processes would result in competitive harm to the laboratories 
and significantly impede the cooperation of laboratories in fully 
disclosing information to inspectors during laboratory inspections. The 
meeting must be conducted in closed session because disclosure of such 
proprietary laboratory information would significantly impede the 
Department's ability to certify laboratories to meet the standards of 
Subpart C of the Mandatory Guidelines and is therefore protected by 
exemption 9(B) of section 552b of title 5 U.S.C.
    The Board will meet in closed session on June 9, from 8:30 a.m. 
until noon to review and discuss new specimen adulteration methods by 
which persons subject to drug testing may subterfuge the drug test and 
the Department's ability to detect them. This meeting must be conducted 
in closed session since disclosing information on such specimen 
adulteration methods will significantly frustrate the Department's 
ability to assure accurate and reliable drug and specimen validity 
testing, and is therefore protected by exemption 9(B) of section 
552b(c) of title 5 U.S.C.
    A roster of the board members may be obtained from: Mrs. Giselle 
Hersh, Division of Workplace Programs, 5600 Fishers Lane, Rockwall II, 
Suite 815, Rockville, MD 20857, 301-443-6014 (voice). The transcript of 
the open session will be available on the following Web site http://workplace.samhsa.gov. Additional information for this meeting may be 
obtained by contacting the individual listed below.
    Committee Name: Substance Abuse and Mental Health Services 
Administration, Drug Testing Advisory Board.
    Meeting Date: June 8, 2004; 8:30 a.m.-4:30 p.m., June 9, 2004; 8:30 
a.m.-Noon.
    Place: Residence Inn by Marriott, 7335 Wisconsin Avenue, Bethesda, 
Maryland 20814.
    Type: Open: June 8, 2004; 8:30 a.m.-11:30 a.m., Closed: June 8, 
2004; 11:30 a.m.-4:30 p.m., Closed: June 9, 2004; 8:30 a.m.-Noon.

FOR FURTHER INFORMATION CONTACT: Donna M. Bush, Ph.D., Executive 
Secretary, 301-443-6014 (voice) or 301-443-3031 (fax).

Patricia Bransford,
Director, Division of Management Systems, SAMHSA.
[FR Doc. 04-12238 Filed 5-28-04; 8:45 am]
BILLING CODE 4162-20-P